The Reallocation: What GLP-1 Is Doing to Consumer Markets and Why Most Marketing Strategy Is Missing It

Something is happening to your customers and it did not show up in last quarter's numbers.

1 in 8 US adults is currently taking a GLP-1 medication. Ozempic, Wegovy, Mounjaro, Zepbound. That figure doubled in 18 months. The trade press noticed the fast food angle. A few packaged food companies mentioned it on earnings calls. Then the coverage moved on.

It should not have moved on.

This is not a diet trend or a cycle. It is a pharmacological intervention at population scale, and it is reorganizing consumer behavior across every impulse-driven category simultaneously. Plate Lunch Collective built ImpulseIndex to track what that looks like in the data. This piece is the argument those numbers are making.

Everyone covered the weight loss story. Fewer calories consumed, less fast food spending. That part is true. It is also the least interesting part of what is happening.

GLP-1 drugs do not just turn down hunger. They turn down the brain's reward signal. The same pathway that produces a food craving also produces the urge for another drink, another hand at the table, another thing in the cart at checkout. GLP-1 blunts all of it. Not as a side effect. As a direct consequence of how the drug works.

This is why GLP-1 users are drinking less without anyone telling them to. A BMJ cohort study of 600,000 US veterans documented an 18% lower risk of alcohol use disorder among GLP-1 users compared to non-users. Nobody prescribed sobriety. The drug produced it. A 2024 PMC analysis of GLP-1 user communities found spontaneous reports of reduced gambling urges and compulsive shopping alongside the drinking reductions, consistent with the same mechanism operating across categories. A 2023 paper in Addiction Biology identified nicotine reward attenuation as a measurable effect now moving into human trials.

If your business depends on people acting on impulse, you are in a different market than you were three years ago. The question is whether your strategy knows it yet.

ImpulseIndex tracks 20 verticals for GLP-1 behavioral signal across two domains: 11 consumer markets and 9 clinical impact categories. Reading them together reveals something no single-vertical analysis captures.

Food service and fast food (Declining). The most documented consumer category. McDonald's, Yum! Brands, and major packaged food companies have all acknowledged GLP-1 headwinds in earnings calls. Cornell University research found an 8 percent decline in fast food and coffee spending within six months of GLP-1 initiation. Snack, convenience, and ultra-processed categories are most exposed. The impulse sale is contracting. The considered purchase is not.

Alcohol sales (Declining). The BMJ cohort data is the clearest number in this space. A hazard ratio of 0.82 for alcohol use disorder among GLP-1 users in a cohort of over 600,000 US veterans. Population scale, not self-reported. A Morgan Stanley AlphaWise survey of 300 GLP-1 users found 62 percent reported reduced alcohol consumption frequency. Beer and spirits are looking at a demand headwind the trade press has not yet quantified at category level.

Rx and prescription volume (Growing). FAIR Health documented a 364 percent relative increase in GLP-1 prescriptions between 2019 and 2024. Medicare Part D claims data confirms the trajectory. Insurance coverage expansion is the primary driver of continued acceleration.

Sports nutrition (Growing). Numerator household panel data found a 38 percent increase in protein shake spending among GLP-1 households. The mechanism is straightforward: GLP-1 users eating significantly less food face a genuine challenge hitting protein targets on reduced caloric intake. Clear whey isolates, protein-fortified beverages, and creatine are all seeing demand from a cohort that previously had no reason to use them.

Cosmetic and aesthetic (Growing). A Johns Hopkins study published in Aesthetic Surgery Journal documented 54 percent annual growth in aesthetic procedures among GLP-1 users following FDA approval. Rapid weight loss produces skin laxity and facial volume loss that medication alone does not resolve. Body contouring, skin tightening, and injectable fillers are the downstream procedures.

Life insurance (Growing). Munich Re has documented a 0.5 percent annual mortality improvement rate attributable to GLP-1 adoption at the high estimate. Actuaries are beginning to price the long-term mortality improvement into underwriting models. Users who previously paid obesity-rated premiums are seeking re-underwriting at standard rates.

Gaming and gambling (Monitoring). GLP-1 receptors are expressed in the nucleus accumbens and ventral tegmental area, the brain's core reward circuitry. Gambling is architecturally dependent on this pathway. The direction of effect is genuinely uncertain. The only peer-reviewed clinical evidence is a single case report (Grant and Chamberlain, Journal of Clinical Psychopharmacology, 2026) documenting gambling disorder remission in one patient. A separate hypothesis letter (Playford and Deahl, QJM, 2024) argues the opposite: that GLP-1 agonists may cause impulse control disorders through elevated dopamine turnover. No registered clinical trials exist. ImpulseIndex tracks this as an unresolved evidence gap.

Creator economy (Monitoring). A Harris Poll found 43 percent of GLP-1 users report decreased engagement with food-related social media content. Wellness, fitness, and body recomposition content is growing within the same category. GLP-1 is reallocating attention within the creator economy, not simply contracting it. Net effect on creator revenue and platform engagement is still resolving.

Airlines (Monitoring). Dentsu survey data found 26 percent of GLP-1 users report flying more often. The structural signal is passenger weight distribution at population scale, which affects fuel economics and seat configuration economics over a multi-year horizon. No airline has yet disclosed a GLP-1 specific impact in an earnings call.

Fitness clubs and gyms (Monitoring). Dentsu data found 47 percent of GLP-1 users report increased gym attendance. Clinical data shows GLP-1 users are more likely to initiate structured exercise once the medication reduces the friction of beginning. The monitoring classification reflects genuine directional complexity: gym membership growth from this cohort is real, but the category simultaneously faces long-term structural questions about what fitness motivation looks like when the primary historical driver, weight loss anxiety, is pharmacologically addressed.

Dating and relationships (Monitoring). Dentsu survey data found 70 percent of GLP-1 users report improved relationship quality. Dating app engagement is changing as body image and social confidence shift. The downstream effects on relationship formation, dissolution, and dating platform economics are still early stage.

Addiction and rehabilitation (Declining). The strongest mechanistic and observational data in the entire ImpulseIndex dataset. The BMJ cohort study of over 600,000 US veterans found GLP-1 use associated with hazard ratios of 0.82 for alcohol use disorder, 0.86 for cannabis use disorder, 0.80 for cocaine use disorder, and 0.75 for opioid use disorder. Population-scale numbers across multiple substance categories. Rehabilitation facilities face a structural demand headwind as incidence and relapse rates decline.

Tobacco and nicotine (Declining). The same BMJ cohort found a hazard ratio of 0.80 for incident nicotine use disorder among GLP-1 users. The reward pathway mechanism driving alcohol reduction appears to extend to nicotine. Tobacco manufacturers and nicotine replacement therapy markets face a headwind not yet reflected in category-level trade analysis.

Reproductive health and fertility (Growing). A controlled trial published in Metabolism and Target Organ Damage found 86.87 percent menstrual cyclicity restoration in GLP-1 users versus 60 percent in controls. GLP-1-driven PCOS resolution is restoring ovulation in patients who had previously been categorized as infertile. Unexpected pregnancies in this cohort are a documented clinical phenomenon. Downstream demand across fertility services and maternity categories is growing.

Chronic pain and rheumatology (Growing). The NEJM STEP 9 trial found a 41.7 point WOMAC pain score reduction in semaglutide-treated patients versus 27.5 points in placebo. GLP-1's anti-inflammatory effects are producing documented remissions in osteoarthritis and inflammatory conditions. Demand for GLP-1 as adjunct therapy in rheumatology is growing while existing biologic treatment markets face pressure from a patient cohort achieving remission through a different mechanism.

Dermatology (Growing). A case report in the Journal of Clinical and Aesthetic Dermatology documented a 92.2 percent reduction in PASI score in a psoriasis patient on GLP-1 therapy. Hidradenitis suppurativa and rare blistering conditions are showing remission. New patient cohorts are entering dermatology practices specifically because of GLP-1 effects on inflammatory skin conditions.

Sleep medicine (Monitoring). The SURMOUNT-OSA trial found tirzepatide, a dual GIP/GLP-1 receptor agonist, reduced the apnea-hypopnea index by 63 percent. This is a direct signal for CPAP manufacturers, sleep medicine practice volumes, and the broader sleep disorder therapeutics market. The monitoring classification reflects genuine mixed net effects: the drug is resolving a condition that historically required ongoing device therapy, which contracts one market while growing another.

Psychiatric and behavioral health (Monitoring). A Lancet Psychiatry cohort study of 95,000 patients found GLP-1 use associated with an adjusted hazard ratio of 0.56 for worsening depression and 0.62 for worsening anxiety. A Nature Medicine study found a hazard ratio of 0.27 for incident suicidal ideation in an overweight and obesity cohort of 240,618 patients. The monitoring classification reflects genuine directional uncertainty: reduced psychiatric symptom burden has complex and potentially bidirectional effects on psychopharmaceutical markets and behavioral health practice volumes.

Neurology and cognitive health (Monitoring). A retrospective cohort study published in Alzheimer's and Dementia found semaglutide associated with a 40 to 70 percent reduced risk of first-time Alzheimer's diagnosis in over one million Type 2 diabetes patients. The EVOKE and EVOKE+ Phase 3 trials published in April 2026 found semaglutide did not slow clinical progression in patients who already have Alzheimer's disease. The observational signal for prevention is strong. The interventional signal for treatment is negative. ImpulseIndex classifies this as Monitoring pending further Phase 3 data.

Hepatology and liver disease (Monitoring). The SYNERGY-NASH trial found tirzepatide achieved 62 percent MASH resolution versus 10 percent placebo at 52 weeks. This is a direct signal for the NASH therapeutics pipeline, one of the most actively invested areas in pharmaceutical development. The monitoring classification reflects the early stage of the commercial signal: the trial data is strong, but market-level effects on hepatology procedure volumes and competing therapeutics pipelines are not yet resolved.

Morgan Stanley covers food and beverage. Bernstein covers apparel. Cornell covers grocery spending. The research exists by vertical. Nobody assembled it across verticals in a form a marketing practitioner could use.

That is part of the problem. The deeper part is the planning cycle. Most marketing strategy runs on 90 days. GLP-1's behavioral effects are a 36-month story. The two timelines do not fit. So the quarterly dashboard shows nothing alarming, the planning meeting moves on, and the structural shift keeps compounding underneath the numbers.

The brands getting ahead of this are not the ones with the best research teams. They are the ones asking a different question. Not what is GLP-1 doing to our category this quarter, but what does our customer look like in 2028 if adoption continues at this rate, and are we building for that customer or for the one we had in 2022.

Your buyers are using AI assistants to research this. That is not a prediction. It is what is happening now.

When a CMO or brand manager asks ChatGPT or Perplexity about GLP-1's effect on their category, the model retrieves from whatever is indexed and authoritative at that moment. The brands and research properties with structured, attributed, specific content on this topic are the ones getting cited. The ones without it are absent from that conversation entirely, regardless of how significant their actual exposure is.

AI search systems break complex queries into components and retrieve the best available answer to each one independently. A general statement about GLP-1 and consumer spending does not retrieve for the specific question about alcohol sales. A specific, cited, mechanistically grounded answer does. The content that wins in AI search is the same content that produces useful market intelligence: one question answered completely, with named sources, in language precise enough to be attributable.

There is also a longer-term problem. The large language models powering these systems are trained on available web content continuously. The brands and research properties establishing clear positions on GLP-1's market effects now are shaping what those models will answer from memory in 2027. Waiting until the trend is fully mainstream means the parametric layer forms without you.

If your brand operates in a category with documented GLP-1 exposure and you have not built citation-ready contentaddressing it directly, you are not missing a content opportunity. You are absent from the research conversation your buyers and investors are already having. AI search visibility work for GLP-1-exposed categories starts with getting the content architecture right.

ImpulseIndex classifies each vertical as Contracting, Tailwinds, or Watching based on available mechanism and data evidence. Apply that to your own category before doing anything else. If your revenue model depends on impulse behavior at the point of sale, in the digital cart, at the subscription renewal moment, you are in a contracting category regardless of what this quarter's numbers show.

The 1-in-8 figure reflects current self-reported use. The more important number is the trajectory. CMS BALANCE, the federal coverage expansion that extended GLP-1 access to Medicare and Medicaid beneficiaries in 2025, accelerates the adoption curve. The populations now gaining access are lower-income adults, older adults, and populations disproportionately represented in fast food, convenience retail, alcohol, and gaming revenue. These are not the commercially insured, higher-income early adopters who produced the first wave of behavioral data. When the adoption curve reaches them, the exposure numbers documented today will look conservative.

The question is no longer whether GLP-1 is a threat. That question has been answered. The question is magnitude, timeline, and strategic response. If your content does not answer those questions with specificity and attribution, a competitor's will. That is the answer that gets cited when a buyer or investor asks an AI assistant.